Prospective donors' perspectives on hematopoietic cell donation for cell and gene therapy research and development-Reference-Cited by-同舟云学术

Prospective donors' perspectives on hematopoietic cell donation for cell and gene therapy research and development

Published:2023-04 Issue:4 Volume:18 Page:301-311
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Hamad Lina¹^ORCID,Anthias Chloe²,Gibson Daniel³,O'Leary Ann²,Machin Laura¹⁴^ORCID

Affiliation:

1. Lancaster Medical School, Lancaster University, Lancaster, LA1 4YW, UK

2. Donor and Transplantation Services, Anthony Nolan, London, NW3 2NU, UK

3. Cell and Gene Therapy Services, Anthony Nolan, London, NW3 2NU, UK

4. Faculty of Medicine, Imperial College London, SW7 2AZ, UK

Abstract

Aim: To explore prospective donors' attitudes and perceptions toward donating hematopoietic stem cells (HSCs) for novel treatments research and development (R&D). Methods: A survey was launched by Anthony Nolan (AN) to assess prospective donors' willingness to donate HSCs for novel therapies R&D, and their degree of comfort with the AN collaborating with and receiving payment from external organizations. Results: Most participants (87%) were willing to donate for novel treatment R&D and were comfortable with AN collaborating with external organizations and receiving payment (91% and 80%, respectively). Conclusion: Results reveal an overall positive response toward donating HSCs for R&D. These findings can support stakeholders and policymakers in outlining donation practices that uphold donors' safety and welfare.

Funder

Anthony Nolan

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme-2022-0195

Reference30 articles.

1. European Medicines Agency. Advanced therapy medicinal products: overview (2021). www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview#stem-cells-section

2. US Food and Drug Administration. Approved Cellular and Gene Therapy Products (2022). www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

3. Advances in stem cell research and therapeutic development

4. Medicine. AfR. Regenerative Medicine: The Pipeline Momentum Builds (2022).

5. Cell and Gene Therapy Catapult. The Cell and Gene Therapy Catapult UK clinical trials database (2021). https://ct.catapult.org.uk/clinical-trials-database